RFA for Collaborative Computational Tools for the Human Cell Atlas (01 August 2017)

The Human Cell Atlas is a global effort to create a reference atlas of all cells in the healthy human body as a resource for studies of health and disease.

This endeavor will generate molecular and imaging data across a range of modalities and spatial scales, requiring new probabilistic and integrative approaches for analysis and interpretation, systematic comparison of methods on benchmark datasets, and mechanisms for disseminating these methods to a wide community.

The Chan Zuckerberg Initiative seeks applications for the development of computational tools, algorithms, visualizations, and benchmark datasets in support of this endeavor. Full details here.

Applications due August 28, 2017 by 5:00 PM PT


To access the full RFA, including details on the project specifications, project requirements, eligibility, key dates, and contact information, click here.

To access the full application instructions, click here.

Questions about the RFA? Join us for a Reddit AMA on Monday, August 14, from 10:00AM - 12:00PM PT. You can also email us at

Announcing New Funding opportunities in Regenerative Medicine FOAs (28 April 2017)

These FOAs solicit competitive supplements that focus on innovative solutions to well-recognized challenges in the development of safe and effective regenerative medicine therapies. Emphasis will be given to request that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness.

Eligible award mechanisms for competitive supplements are the R41/42, R43/44, U01, U54, UM1, UM2, UC4, U24, R01, R24, P50, and P41. The twelve Regenerative Medicine FOAs have published in the NIH Guide and may be accessed at the links below. Additional information about the Regenerative Medicine Innovation Project, including a set of Frequently Asked Questions, can be found at

RFA-HL-17-023 , R43 /R44 Small Business Innovation Research (SBIR) Grant - Phase I, Phase II, Phase IIB, and Fast Track

RFA-HL-17-024 , R41 /R42 Small Business Technology Transfer (STTR) Grant - Phase I, Phase II, Phase IIB, and Fast Track

RFA-HL-17-025 , U54 Specialized Center- Cooperative Agreements

RFA-HL-17-026 , UM1 Research Project with Complex Structure Cooperative Agreement

RFA-HL-17-027 , UC4 High Impact Research and Research Infrastructure - Cooperative Agreement Programs

RFA-HL-17-028 , U24 Resource-Related Research Projects – Cooperative Agreements

RFA-HL-17-029 , R01 Research Project Grant

RFA-HL-17-030 , R24 Resource-Related Research Projects

RFA-HL-17-031 , UM2 Program Project or Center with Complex Structure Cooperative Agreement

RFA-HL-17-032 , P50 Specialized Center

RFA-HL-17-033 , P41 Biotechnology Resource Grants

RFA-HL-17-034 , U01 Research Project – Cooperative Agreements

Announcing New DiaComp Funding opportunity in Human Tissue Interrogation (20 March 2017)

Applications of 5 pages requesting up to $100,000 for one year are due June 12, 2017.

Current areas of emphasis include:

  • Human Tissue Interrogation Develop and use innovative technologies to analyze human tissue from end organs of diabetic complications. For example:

    • Develop new protocols, tools or reagents for the molecular/omic interrogation of healthy or diseased human tissue. These may involve imaging methods at the single cell level (e.g., SWITCH, systems-wide control of interaction time and kinetics of chemicals, CyTOF mass cytometry, CLARITY, etc.) or digestion of specimens into single cells for further analysis (e.g, flow cytometry, microfluidics, mass cytometry or chemical cytometry).

    • Profile and validate cell types isolated from healthy or diseased human tissue using FACS, laser-capture or other approaches. Molecular/omic profiling of cell types should inform in vitro and in vivo efforts to model, recreate or regenerate these cell types.

    • Examine the localized tissue secretory and cellular microenvironments (e.g., extracellular matrix, interstitium, wound exudate) using emerging technologies such as nanoFACS for extracellular vesicle profiling, CLASI-FISH for exploring the 3D relationships in the microbiome, or MALDI-based technologies to characterize the extracellular proteome as it relates to the development or extent of diabetic complications.

    • Bioengineer healthy or diseased end organs of diabetic complications, including incorporation of appropriate cell types, for functional testing and screening.

For more information about this opportunity and how to apply, please visit: